Generate BiomedicinesGENB +2.18%6 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,324 Biotechnology companies, Generate Biomedicines ranks worse than 75528.63% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Generate Biomedicines does not have enough data to calculate 3-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Generate Biomedicines 3-Year ROIIC % Related Terms
Generate Biomedicines 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Generate Biomedicines's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines 3-Year ROIIC % Chart
Generate Biomedicines Annual Data
Trend
Dec24
Dec25
3-Year ROIIC %
0.00
0.00
Generate Biomedicines Semi-Annual Data
Dec24
Dec25
3-Year ROIIC %
0.00
0.00
GENB vs PVLA, SLBT, NKTR: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Generate Biomedicines's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's 3-Year ROIIC % falls into.
Generate Biomedicines's 3-Year ROIIC % for the quarter that ended in is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( () - () )
/
( () - () )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Generate Biomedicines (GENB) has a 3-Year ROIIC % of 0.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #999999 out of 1324 companies in the Biotechnology industry.
Is Generate Biomedicines' 3-Year ROIIC % too high?
Generate Biomedicines' current 3-Year ROIIC % is 0.00. Based on the distribution chart, Generate Biomedicines ranks #999999 out of 1324 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' 3-Year ROIIC % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #999999 out of 1324 companies for 3-Year ROIIC %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 